公开(公告)号：US11185481B2

公开(公告)日：2021-11-30

申请号：US15224844

申请日：2016-08-01

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)

Inventor： Sai Kiang Lim ,  Mathew Sze Wei Yeo ,  Tian Sheng Chen ,  Ruenn Chai Lai

IPC: A61K8/14 ,  A61P17/02 ,  A61K8/98 ,  A61K35/28 ,  A61K9/00 ,  A61Q7/00 ,  A61P17/14 ,  A61K38/17 ,  A61K38/02

Abstract: We describe the use of an exosome for the preparation of a pharmaceutical composition to promote or enhance would healing or hair growth, or both, in an individual. The exosome may be derived from a stem cell such as a mesenchymal stem cell (MSC).

公开(公告)号：US10024820B2

公开(公告)日：2018-07-17

申请号：US14658088

申请日：2015-03-13

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Ruige Wu ,  Zhiping Wang ,  Sai Kiang Lim ,  Yen Peng Daphne Seah

IPC: G01N27/447 ,  B65B3/04

Abstract: According to embodiments of the present invention, a microfluidic device for gel electrophoresis is provided. The microfluidic device includes a sample channel configured to receive a sample; a stacking channel comprising a preloaded stacking reagent; and a separation channel comprising a preloaded separation reagent, wherein the preloaded stacking reagent has a physical characteristic different from that of the preloaded separation reagent; and wherein the sample channel, the stacking channel and the separation channel are in fluid communication with one another. According to further embodiments of the present invention, a method of manufacturing a microfluidic device for gel electrophoresis is also provided.

公开(公告)号：US10481166B2

公开(公告)日：2019-11-19

申请号：US15970952

申请日：2018-05-04

Applicant: Agency for Science, Technology and Research ,  Singapore Health Services Pte Ltd.

Inventor： Sai Kiang Lim ,  Kok Hian Tan

IPC: C12N1/00 ,  G01N33/68 ,  G01N33/50

Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phos—photidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.

公开(公告)号：US20160025739A1

公开(公告)日：2016-01-28

申请号：US14773677

申请日：2014-03-12

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  SINGAPORE HEALTH SERVICES PTE LTD

Inventor： Sai Kiang Lim ,  Kok Hian Tan

IPC: G01N33/68 ,  A61K33/06 ,  A61K31/502 ,  A61K31/4422 ,  A61K31/4439 ,  A61K31/166

CPC classification number: G01N33/689 ,  A61K31/166 ,  A61K31/4422 ,  A61K31/4439 ,  A61K31/502 ,  A61K33/06 ,  G01N33/6893 ,  G01N2333/4727 ,  G01N2333/495 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2333/585 ,  G01N2333/70596 ,  G01N2333/71 ,  G01N2333/8132 ,  G01N2333/8146 ,  G01N2333/9129 ,  G01N2570/00 ,  G01N2800/368 ,  G01N2800/52 ,  G01N2800/60 ,  Y02A50/471

Abstract: We describe a method of detecting pre-eclampsia in a cell, tissue, organ or organism, the method comprising detecting a modulated level of expression, activity or amount of a pre-eclampsia biomarker polypeptide selected from the group consisting of PlGF, FLT1, BNP, ANP, CD9, PAI-1, TGF β, PCT, SI 00b, TIMP1, CD 105 and IL6 in or of a microparticle type (selected from a CTB binding microparticle and an Annexin V binding microparticle) from the cell, tissue, organ or organism, as compared to level of expression, activity or amount of the pre-eclampsia biomarker polypeptide in the same microparticle type in a cell, tissue, organ or organism not sufferin from pre-eclampsia.

Abstract translation: 我们描述了一种检测细胞，组织，器官或生物体中先兆子痫的方法，所述方法包括检测选自PlGF，FLT1，BNP的先兆子痫生物标志物多肽的表达，活性或量的调节水平 ，选自CTB结合微粒和膜联蛋白V结合微粒的微粒型（选自CTB结合微粒和膜联蛋白V结合微粒）中的ANP，CDP4，PAI-1，TGFβb，PCT，SI00b，TIMP1，CD105和IL6， 与先前先兆子痫不同的细胞，组织，器官或生物体中相同微粒类型中的先兆子痫生物标记多肽的表达水平，活性或量的水平与器官或生物体相比。

公开(公告)号：US20150125950A1

公开(公告)日：2015-05-07

申请号：US14401872

申请日：2013-05-17

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) ,  SINGAPORE HEALTH SERVICES PTE LTD

Inventor： Sai Kiang Lim ,  Kok Hian Tan

IPC: C12N5/0775

CPC classification number: C12N5/0668 ,  A61K35/28 ,  A61K35/51 ,  C12N5/0665 ,  C12N2500/02 ,  C12N2510/04

Abstract: We describe a method of cell culture of an umbilical mesenchymal stem cell (MSC). The method comprises the steps of providing an umbilical mesenchymal stem cell (MSC) and culturing the umbilical mesenchymal stem cell in a cell culture medium under hypoxic conditions. The umbilical mesenchymal stem cell may be transformed with an oncogene such as c-myc. Conditioned media and exosomes obtained from the umbilical mesenchymal stem cell may be used for therapy.

Abstract translation: 我们描述了脐带间充质干细胞（MSC）的细胞培养方法。 该方法包括在缺氧条件下在细胞培养基中提供脐带间充质干细胞（MSC）并培养脐带间充质干细胞的步骤。 可以用诸如c-myc的致癌基因转化脐带间充质干细胞。 从脐带间充质干细胞获得的条件培养基和外来体可用于治疗。

公开(公告)号：US10780128B2

公开(公告)日：2020-09-22

申请号：US14444105

申请日：2014-07-28

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)

Inventor： Sai Kiang Lim

IPC: A61K35/00 ,  A61K35/28 ,  A61K35/12 ,  C12N5/0775 ,  A61K9/00 ,  A61K9/10 ,  A61K47/24 ,  A61K47/28

Abstract: We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.

公开(公告)号：US20170020925A1

公开(公告)日：2017-01-26

申请号：US15188794

申请日：2016-06-21

Applicant: Agency for Science, Technology and Research

Inventor： Sai Kiang Lim

IPC: A61K35/28 ,  C12N5/0775 ,  C12Q1/68

CPC classification number: A61K35/28 ,  C12N5/0662 ,  C12N2510/00 ,  C12Q1/6809 ,  C12Q1/6876 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/5073 ,  G01N33/5091 ,  C12Q2545/114 ,  C12Q2525/207

Abstract: We describe a method of monitoring the state of a cell, the method comprising establishing, for a selected microRNA (miRNA) species secreted by the cell, a ratio of: (a) a precursor form of the miRNA species (pre-miRNA); to (b) a mature form of the miRNA species (mature miRNA); in which the pre- to mature miRNA ratio so established is indicative of the state of the cell. We also describe a method comprising the steps of: (a) providing a mesenchymal stem cell (MSC); and (b) introducing an oncogene into the mesenchymal stem cell to thereby transform it; in which the transformed mesenchymal stem cell does not secrete a gene product of the oncogene into a medium in which it is grown.

Abstract translation: 我们描述了一种监测细胞状态的方法，所述方法包括针对由细胞分泌的选定的微小RNA（miRNA）物种确定：（a）miRNA物种（前体miRNA）的前体形式的比例; 到（b）成熟形式的miRNA物种（成熟miRNA）; 其中如此建立的预成熟miRNA比例指示细胞的状态。 我们还描述了一种方法，其包括以下步骤：（a）提供间充质干细胞（MSC）; 和（b）将癌基因导入间充质干细胞，从而将其转化; 其中转化的间充质干细胞不将癌基因的基因产物分泌到其中生长的培养基中。

公开(公告)号：US09977032B2

公开(公告)日：2018-05-22

申请号：US15219820

申请日：2016-07-26

Applicant: Agency for Science, Technology and Research ,  Singapore Health Services Pte Ltd.

Inventor： Sai Kiang Lim ,  Kok Hian Tan

IPC: C12N1/00 ,  G01N33/68 ,  G01N33/50

CPC classification number: G01N33/689 ,  G01N33/5091 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2405/10 ,  G01N2800/32 ,  G01N2800/368 ,  G01N2800/52 ,  G01N2800/7028

Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phosphotidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.

公开(公告)号：US20150260682A1

公开(公告)日：2015-09-17

申请号：US14658088

申请日：2015-03-13

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Ruige WU ,  Zhiping Wang ,  Sai Kiang Lim ,  Yen Peng Daphne Seah

IPC: G01N27/447 ,  B65B3/04

CPC classification number: G01N27/44791 ,  G01N27/44782

Abstract: According to embodiments of the present invention, a microfluidic device for gel electrophoresis is provided. The microfluidic device includes a sample channel configured to receive a sample; a stacking channel comprising a preloaded stacking reagent; and a separation channel comprising a preloaded separation reagent, wherein the preloaded stacking reagent has a physical characteristic different from that of the preloaded separation reagent; and wherein the sample channel, the stacking channel and the separation channel are in fluid communication with one another. According to further embodiments of the present invention, a method of manufacturing a microfluidic device for gel electrophoresis is also provided.

Abstract translation: 根据本发明的实施例，提供了一种用于凝胶电泳的微流体装置。 微流体装置包括构造成接收样品的样品通道; 堆叠通道，包括预加载的堆叠试剂; 以及包含预加载的分离试剂的分离通道，其中所述预加载的堆叠试剂具有与所述预加载的分离试剂的物理特性不同的物理特性; 并且其中所述样品通道，所述堆叠通道和所述分离通道彼此流体连通。 根据本发明的另外的实施方案，还提供了制造用于凝胶电泳的微流体装置的方法。

公开(公告)号：US09005897B2

公开(公告)日：2015-04-14

申请号：US13788627

申请日：2013-03-07

Applicant: Agency for Science, Technology and Research

Inventor： Sai Kiang Lim ,  Elias Lye

IPC: C12Q1/68 ,  C12N5/071 ,  G01N33/50 ,  C12N5/0775

CPC classification number: C12N5/0603 ,  C12N5/0662 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/734 ,  C12N2502/1352 ,  C12N2506/02 ,  C12Q1/6809 ,  G01N33/5044

Abstract: We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.